Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Income | $1,175.9M | $1,528.6M | $1,532.3M | $1,643.0M | $2,441.2M | $2,789.6M | $3,356.6M | $4,169.1M | $5,076.9M | $5,596.9M | $6,142.8M | $7,356.6M | $7,194.8M | $7,429.5M | $7,480.9M | $7,859.4M | $8,278.5M | $9,320.3M | $10.6B | $14.9B |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Novo Nordisk A/S's last 12-month Operating Income is $17.2B, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Novo Nordisk A/S's Operating Income growth was 43.2%. The average annual Operating Income growth rates for Novo Nordisk A/S have been 27.8% over the past three years, 17.3% over the past five years.
Over the last year, Novo Nordisk A/S's Operating Income growth was 43.2%, which is higher than industry growth of (0.1%). It indicates that Novo Nordisk A/S's Operating Income growth is Good.